Monday, November 30, 2020 NIH Announces Restructured HIV Clinical Trials Networks NIAID today announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years to conduct the innovative, efficient clinical research needed to accelerate progress against the HIV pandemic. NIAID also awarded grants to 35 U.S. and international institutions selected as HIV clinical trials units. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107

Experimental Vaccine for Crimean-Congo Hemorrhagic Fever

Monday, November 30, 2020 Experimental Vaccine for Deadly Tickborne Virus Effective in Cynomolgus Macaques An experimental vaccine developed by NIAID scientists and European colleagues against Crimean-Congo hemorrhagic fever virus has protected cynomolgus macaques in a new study published in Nature Microbiology. The scientists used the DNA-based vaccine to prevent infection by CCHFV, a tickborne virus found in the Middle East, Asia, Africa and parts of Europe. The virus also can be transmitted to people by direct contact with infected fluids or tissue from people or certain livestock species. CCHFV infects up to 15,000 people annually, according to the World Health Organization. About 1 in 8 of those who are infected develop severe disease, which leads to about 500 deaths each year. CCHFV also is considered a possible agent of bioterrorism. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107

NIH announces restructured HIV clinical trials networks

Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).   NIH announces restructured HIV clinical trials networks 11/30/2020 01:00 PM EST Grant awards set stage for next seven years of science-driven HIV clinical research. Update Your E-mail Address | Add Subscriptions | Unsubscribe All If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®  This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612

NINR News and Notes Digest: November 2020

NINR's online newsletter, providing the latest nursing science discoveries, funding and training opportunities, and news.

Having trouble viewing this email? View it as a Web page. November 2020 NINR News & Notes News & Notes is NINR's online newsletter, providing the latest nursing science discoveries, funding and training opportunities, and news about our events and initiatives.   Office of the Director Announcing the Development of NINR's Next Strategic Plan Dr. Shannon Zenk has posted a new message on thinking boldly, embracing change, and new opportunities as NINR develops its next strategic plan. Dr. Zenk highlights that NINR is committed to making the planning process transparent, and to gathering input from the community at various points in the process. Read More Events Dr. Shannon Zenk to Present the 2020 Stephen E. Straus Distinguished Lecture On December 9, 2020 from 12:00 to 1:00 p.m. ET, NINR Director Dr. Shannon Zenk will give the 2020 Stephen E. Straus Distinguished Lecture, hosted by the National Center for Complementary and Integrative Health (NCCIH). Read More   Register Now for Symptom Science Advances in Oncology Nursing Virtual Colloquium Registration is now open for Symptom Science Advances in Oncology Nursing, a colloquium presented by the National Institute of Nursing Research, the National Cancer Institute Center for Cancer Research, and the Oncology Nursing Society. Read More   Training NINR's Summer Genetics Institute Cancelled for 2021 To align with current NIH guidance on travel and meetings, NINR has decided to cancel its Summer Genetics Institute for 2021. Read More     To view or modify your subscription preferences or unsubscribe entirely, please visit the Subscriber Preferences Page. Our mailing address is: 31 Center Drive, Room 5B03 Bethesda, MD 20892-2178

 

---

Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

This service is provided to you at no charge by The National Institute of Nursing Research.

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud, on behalf of: National Institute of Nursing Research National Institutes of Health · 31 Center Drive, Room 5B10 · Bethesda, MD 20892-2178

Experimental Vaccine for Deadly Tickborne Virus Effective in Cynomolgus Macaques

Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).   Experimental Vaccine for Deadly Tickborne Virus Effective in Cynomolgus Macaques 11/30/2020 11:00 AM EST Monkeys protected against CCHFV, which infects thousands of people annually. Update Your E-mail Address | Add Subscriptions | Unsubscribe All If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®  This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612

FDA Expands Approval of Cancer Liquid Biopsy - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Cancer "Liquid Biopsy" Blood Test Gets Expanded FDA Approval 11/30/2020 FDA has expanded the approved uses of the FoundationOne Liquid CDx blood test, known as a liquid biopsy, that can help doctors pick specific treatments for some people with cancer. When used in this way, the test is known as a companion diagnostic.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892